Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA Combined with Immunotherapy in Advanced Hepatocellular Carcinoma
NCT07064668Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tauroursodeoxycholic acid in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07064668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064668.